Search
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalIt is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Synthetic Conjugated Estrogens, B
go.drugbank.com/drugs/DB09318ApprovedHowever, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control … Although many of them contain several compounds in common (such as the estrogen derivatives sodium estrone sulfate and sodium equilin sulfate), they vary by their original source (such as horse-, human
TRGFT-201
go.drugbank.com/drugs/DB23064ApprovedInvestigational[L64070,L64071] It is the first regulatory T cell (Treg)-based immunotherapy approved by the FDA.[L64071] … [L64070] It is a precision-engineered graft composed of three cell populations isolated from an HLA-matched donor's mobilized peripheral blood — purified hematopoietic stem and progenitor cells (HSPCs)
Abarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnIt is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Metiamide
go.drugbank.com/drugs/DB08805ExperimentalMetiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.
Inosine pranobex
go.drugbank.com/drugs/DB13156ApprovedInosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
Micronomicin
go.drugbank.com/drugs/DB13274ApprovedMicronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
DADLE
go.drugbank.com/drugs/DB08856ExperimentalIt can cause transient depression of mean arterial blood pressure and heart rate.
Zofenopril
go.drugbank.com/drugs/DB13166ApprovedInvestigationalIt is an angiotensin-converting enzyme (ACE) inhibitor.
Buspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalBuspirone was first approved in 1986 by the FDA [A181751] and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety.